Kei Muro
#146,579
Most Influential Person Now
Researcher
Kei Muro's AcademicInfluence.com Rankings
Kei Murocomputer-science Degrees
Computer Science
#7394
World Rank
#7788
Historical Rank
Machine Learning
#2709
World Rank
#2744
Historical Rank
Artificial Intelligence
#3005
World Rank
#3051
Historical Rank
Database
#4455
World Rank
#4632
Historical Rank
Download Badge
Computer Science
Kei Muro's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Kei Muro Influential?
(Suggest an Edit or Addition)Kei Muro's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. (2014) (1712)
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1426)
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial (2018) (1140)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012) (965)
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. (2016) (860)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019) (846)
- Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. (2000) (810)
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (2018) (791)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015) (679)
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort (2016) (651)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011) (648)
- Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin (2004) (556)
- Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. (2013) (425)
- Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. (1999) (395)
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. (2020) (380)
- Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS (2018) (370)
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. (2018) (368)
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. (2017) (302)
- Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). (2011) (291)
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. (2012) (279)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 (2018) (277)
- A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation (2007) (260)
- Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. (2004) (233)
- A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. (2004) (224)
- Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. (2013) (213)
- Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. (2010) (207)
- Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). (2010) (205)
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study. (2019) (192)
- Comprehensive registry of esophageal cancer in Japan, 2013 (2020) (169)
- Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study (2019) (158)
- KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. (2017) (156)
- Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). (2016) (146)
- Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. (1997) (145)
- Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. (2015) (144)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (142)
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data (2019) (129)
- An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. (1998) (129)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. (2017) (126)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (117)
- APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis. (1997) (115)
- Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. (2002) (112)
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. (2021) (111)
- Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. (2017) (100)
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer (2014) (100)
- Comprehensive registry of esophageal cancer in Japan, 2012 (2019) (98)
- Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer (2015) (95)
- Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines (2014) (94)
- Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). (2010) (91)
- Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. (2004) (91)
- Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients (2013) (87)
- A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors (2019) (85)
- A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy (2011) (85)
- Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. (2004) (83)
- Comprehensive Registry of Esophageal Cancer in Japan, 2010 (2017) (83)
- Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. (2018) (80)
- Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment (2013) (78)
- Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). (2015) (78)
- Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study (2017) (78)
- Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil (2003) (76)
- Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. (2009) (75)
- Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer (2014) (72)
- Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy (2011) (71)
- Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. (2006) (70)
- Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer (2016) (69)
- KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. (2017) (69)
- Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison (2017) (67)
- Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. (2000) (67)
- Regioselective monosulfation and disulfation of the phytoestrogens daidzein and genistein by human liver sulfotransferases. (2004) (66)
- A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia (2019) (64)
- Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese (2009) (64)
- Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. (2015) (63)
- Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate (2010) (63)
- Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts (2004) (63)
- The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer (2017) (63)
- 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. (2016) (62)
- Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). (2020) (61)
- LBA15A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER (2014) (60)
- Comprehensive Registry of Esophageal Cancer in Japan, 2011 (2018) (60)
- Morbidity and mortality after self-expandable metallic stent placement in patients with progressive or recurrent esophageal cancer after chemoradiotherapy. (2003) (58)
- A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. (2016) (58)
- Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study (2015) (57)
- Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. (2011) (57)
- Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma† (2016) (57)
- Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4. (2006) (56)
- A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. (2009) (56)
- Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G (2016) (54)
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial (2021) (53)
- Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) (2016) (53)
- Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data (2017) (51)
- Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. (2011) (51)
- Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study (2015) (51)
- Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. (2012) (50)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. (2016) (50)
- Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02) (2018) (50)
- Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study (2017) (50)
- Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: A retrospective study (2010) (50)
- Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer (2010) (46)
- Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan (2003) (46)
- A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) (2018) (46)
- Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). (2017) (45)
- Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy. (2012) (44)
- A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). (2016) (44)
- Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS‐102 (2017) (44)
- Comprehensive Registry of Esophageal Cancer in Japan, 2002 (2010) (43)
- Small cell carcinoma of the esophagus. Analysis of 14 cases and literature review. (2005) (42)
- Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae (1999) (42)
- Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE‐012 (2018) (42)
- Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma (2013) (41)
- Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer (2019) (41)
- Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer (2003) (41)
- LBA28_PRKEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer (2017) (40)
- Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study (2018) (40)
- No prognostic significance of p53 expression in esophageal squamous cell carcinoma (1999) (40)
- Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab (2021) (40)
- Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial (2018) (39)
- Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11 (2015) (39)
- Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial (2021) (38)
- A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First‐line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study (2018) (37)
- Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer (2019) (37)
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version) (2018) (36)
- A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). (2018) (34)
- Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer (2016) (34)
- Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial (2018) (33)
- The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. (2019) (33)
- Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer (2018) (32)
- A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) (2014) (32)
- Comprehensive registry of esophageal cancer in Japan, 2014 (2021) (32)
- Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2016) (31)
- Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial) (2019) (31)
- The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. (2013) (31)
- Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (2017) (31)
- Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. (2009) (31)
- Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A) (2017) (31)
- Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting. (2019) (31)
- Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. (1996) (30)
- Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival. (2016) (30)
- Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer (2010) (30)
- Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials (2020) (30)
- A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial. (2015) (30)
- Comprehensive Registry of Esophageal Cancer in Japan, 2001 (2009) (29)
- Primary squamous cell carcinoma of the stomach: a case report with a review of Japanese and Western literature. (1999) (28)
- Clinical management of EGFRI dermatologic toxicities: the European perspective. (2007) (28)
- The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061. (2020) (28)
- Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials (2012) (28)
- Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. (2006) (28)
- Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10 (2021) (27)
- Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy (2017) (27)
- Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. (2010) (27)
- Comprehensive registry of esophageal cancer in Japan, 2015 (2022) (27)
- A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients (2013) (27)
- Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial. (2020) (27)
- TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study. (2016) (26)
- Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. (2015) (25)
- FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis. (2017) (25)
- Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer (2012) (25)
- Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). (2015) (25)
- 617OA Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) (2017) (25)
- Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy (2017) (24)
- Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer (2012) (24)
- Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. (2019) (24)
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. (2019) (24)
- Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer (2013) (24)
- Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604) (2015) (23)
- Central venous access port-related complications in outpatient chemotherapy for colorectal cancer. (2007) (23)
- Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1. (2008) (23)
- Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer. (2019) (23)
- Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. (2020) (23)
- Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients† (2014) (23)
- Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). (2015) (23)
- Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer (2001) (22)
- A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908) (2005) (22)
- LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC) (2015) (22)
- Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. (2011) (22)
- The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma. (2015) (22)
- Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. (2006) (21)
- Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients. (2018) (21)
- Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer (2014) (21)
- CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy (2014) (21)
- Chemotherapy for patients with advanced gastric cancer with performance status 2. (2009) (21)
- A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study (2014) (20)
- Diagnostic utility of endoscopic ultrasonography for preoperative rectal cancer staging estimation. (1996) (20)
- Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia (2019) (20)
- Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study1 (2018) (20)
- Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. (2012) (20)
- Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report (2019) (20)
- KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. (2017) (20)
- Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy. (2020) (20)
- Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma (2022) (19)
- A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy (2011) (19)
- Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. (2010) (19)
- Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis (2015) (19)
- Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW (2018) (19)
- Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer (2013) (19)
- Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer (2013) (19)
- The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061. (2020) (19)
- Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. (2010) (18)
- A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G). (2014) (18)
- The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. (2018) (18)
- Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma. (2021) (18)
- Prognostic Significance of Sarcopenia in Patients with Unresectable Advanced Esophageal Cancer (2019) (18)
- A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer. (2015) (17)
- Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study (2019) (17)
- Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition (2018) (17)
- A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study (2018) (17)
- Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer (2020) (17)
- Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer (2011) (17)
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study (2017) (17)
- Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines (2012) (17)
- Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain (2013) (17)
- Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. (2019) (17)
- LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. (2017) (16)
- Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059. (2019) (16)
- Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed by Surgery in Elderly Patients with Esophageal Squamous Cell Carcinoma (2020) (16)
- Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis (2016) (16)
- First‐line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study (2012) (16)
- Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis (2012) (16)
- Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer (2020) (15)
- KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. (2018) (15)
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia (2021) (15)
- Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan (2018) (15)
- Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer (2020) (15)
- Clinical Features of Regorafenib‐induced Liver Injury in Japanese Patients From Postmarketing Experience (2017) (15)
- Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study (2018) (15)
- Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil (2020) (15)
- Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set (2018) (15)
- Diagnostic findings in endoscopic screening of superficial colorectal neoplasia: results from a prospective study. (1998) (15)
- A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808) (2015) (14)
- Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G) (2020) (14)
- Systemic chemotherapy for metastatic colorectal cancer -Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for treatment of colorectal cancer. (2017) (14)
- MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study. (2021) (14)
- A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer. (2012) (14)
- Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303) (2017) (14)
- Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. (2009) (14)
- RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results. (2014) (14)
- Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition (2019) (14)
- Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. (2008) (13)
- Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry (2021) (13)
- Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry (2021) (13)
- Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia. (2021) (13)
- Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition (2021) (13)
- A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer (2013) (13)
- Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial. (2018) (13)
- FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study) (2011) (13)
- Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer (2017) (13)
- A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer. (2016) (13)
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors (2019) (13)
- Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis (2019) (12)
- Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors (2018) (12)
- Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08) (2021) (12)
- Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial. (2011) (12)
- Long-term survivor of gastric small cell carcinoma. (2004) (12)
- Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS (2011) (12)
- Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety (2017) (12)
- Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer (2020) (12)
- Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2‐positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study (2019) (12)
- Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin. (2017) (12)
- Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies. (2020) (12)
- Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. (2012) (12)
- Retrospective analysis of clinical results and predictors of response in chemo-naïve patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy (2004) (11)
- Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08). (2021) (11)
- The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase I trial in Japanese patients with metastatic solid tumors. (2011) (11)
- Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy (2017) (11)
- Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study (2019) (11)
- Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): Preliminary results (2008) (11)
- A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer (2015) (11)
- MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. (2022) (11)
- Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer. (2018) (11)
- Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil (2004) (11)
- Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer (2013) (11)
- A phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data. (2018) (11)
- A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data. (2020) (11)
- Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab (2016) (10)
- Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer. (2017) (10)
- Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030). (2016) (10)
- Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy‐naïve Patients With RAS (KRAS/NRAS) Wild‐type, Metastatic Colorectal Cancer (2017) (10)
- Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy (2013) (10)
- Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features (2019) (10)
- Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data (2020) (10)
- Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study . (2017) (10)
- Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC). (2017) (10)
- Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. (1999) (10)
- A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab (2011) (10)
- Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials (2018) (10)
- Small cell carcinoma of the esophagus with an esophago-mediastinal fistula successfully treated by chemoradiation therapy and intubation: a case report. (1993) (10)
- Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-glucuronide: a substudy of the FIRIS study. (2013) (10)
- Improvement of Oral Intake following Chemotherapy in Gastric Cancer Patients with an Inability to Eat (2011) (10)
- Complete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: a case report. (2001) (10)
- Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature (2017) (9)
- Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging (2018) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer (2017) (9)
- Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer. (2006) (9)
- The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation (2019) (9)
- Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer. (2011) (9)
- Proton pump inhibitor use and the efficacy of chemotherapy in metastatic colorectal cancer: a post hoc analysis of a randomized phase 3 trial (AXEPT). (2021) (9)
- Updated results of the FIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC). (2011) (9)
- Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials (2018) (9)
- LBA17Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors (2017) (9)
- Active salvage chemotherapy versus best supportive care for patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane (2016) (9)
- SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy. (2022) (8)
- Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer. (2011) (8)
- Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC). (2018) (8)
- [mTOR inhibitor]. (2011) (8)
- PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer. (2021) (8)
- Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer (2020) (8)
- PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (2016) (8)
- Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab. (2011) (8)
- Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07) (2021) (8)
- Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment (2014) (8)
- Clinical outcome of definitive radiation therapy for superficial esophageal cancer (2016) (8)
- A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy (2012) (7)
- Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel±trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G). (2018) (7)
- First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study (2018) (7)
- An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial). (2018) (7)
- Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy. (2015) (7)
- Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation. (2017) (7)
- Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). (2016) (7)
- Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant (2012) (7)
- Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (2021) (7)
- O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma (2020) (7)
- Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms (2018) (7)
- Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis (2019) (7)
- Clinical management of EGFRI dermatologic toxicities: the Japanese perspective. (2007) (7)
- Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy (2014) (7)
- Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer (2004) (7)
- Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody (2017) (7)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial. (2018) (7)
- DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer. (2019) (7)
- Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure (2018) (7)
- Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy (2016) (7)
- Randomized phase II study of panitumumab (Pmab) + irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G. (2017) (7)
- Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer (2021) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer (2019) (6)
- Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer. (2018) (6)
- Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study. (2018) (6)
- LBA-04Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012 (2015) (6)
- Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study (2017) (6)
- Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients. (2011) (6)
- KEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy (2019) (6)
- A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC): (JCOG 9906) (2007) (6)
- A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index (2022) (6)
- Clinical practice guidelines for duodenal cancer 2021 (2022) (6)
- Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors. (2016) (6)
- Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial (2019) (6)
- Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study (2021) (6)
- Recursive partitioning analysis for new classification of patients with esophageal cancer treated by chemoradiotherapy. (2012) (6)
- PD-014Final survival results and onset of neutropenia as an indicator of therapeutic effect in phase 2 of TAS-102 vs placebo with metastatic colorectal cancer (J003-10040030) (2016) (6)
- The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. (2015) (6)
- PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. (2016) (6)
- Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. (2019) (6)
- A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors (2019) (6)
- 638PTwo year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07) (2017) (6)
- Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). (2020) (6)
- Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G (2020) (6)
- A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer. (2008) (6)
- Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan (2020) (6)
- The effect of CYP 2 C 19 polymorphism on the safety , tolerability , and pharmacokinetics of tivantinib ( ARQ 197 ) : results from a phase I trial in advanced solid tumors (2013) (6)
- An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7) (2021) (5)
- Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1. (2018) (5)
- A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013) (2022) (5)
- Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer (2014) (5)
- Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers (2019) (5)
- Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy (2013) (5)
- A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer. (2020) (5)
- Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases (2020) (5)
- O1-4 Survival time of nivolumab treatment in advanced gastric cancer from real-world data of the DELIVER trial (JACCRO GC-08) (2021) (5)
- A phase I study of the chimeric monoclonal anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a single agent in subjects from Japan with advanced solid tumors: Safety, pharmacokinetics (PK) (2005) (5)
- 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (5)
- A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies (2020) (5)
- Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer. (2012) (5)
- O-007Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study (2016) (5)
- Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 (2021) (5)
- Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer (2011) (5)
- T-ACT (WJOG7112G): A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. (2017) (5)
- KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis. (2018) (5)
- Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC). (2019) (5)
- A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. (2011) (5)
- Definitive chemoradiotherapy may be standard treatment options in clinical stage I esophageal cancer. (2004) (5)
- Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report (2020) (5)
- Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics). (2015) (4)
- Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer (2020) (4)
- Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer (2021) (4)
- Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study (2019) (4)
- 6012 The FIRIS study; A Phase III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as 2nd-line chemotherapy for metastatic colorectal cancer (mCRC) [FIRIS study group] (2009) (4)
- A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial). (2020) (4)
- 1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: Tolerability results and antitumor activity in esophageal carcinoma (2022) (4)
- Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer. (2021) (4)
- aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. (2018) (4)
- Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2) (2020) (4)
- Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. (2017) (4)
- Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer. (2003) (4)
- Case series of cetuximab monotherapy for patients with pre-treated colorectal cancer complicated with hyperbilirubinemia due to severe liver metastasis. (2010) (4)
- A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT). (2016) (4)
- Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment (2016) (4)
- Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181 (2021) (4)
- Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications (2010) (4)
- Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). (2018) (4)
- Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group (2020) (4)
- Prolonged Survival of Patients with Metastatic Colorectal Cancer following First-Line Oxaliplatin-Based Chemotherapy with Molecular Targeting Agents and Curative Surgery (2011) (4)
- Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo. (2017) (4)
- Efficacy of cytotoxic agents after progression of anti-PD-(L)1 antibody for pretreated metastatic gastric cancer. (2018) (4)
- A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer (2022) (4)
- Phase 1b study of andecaliximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma. (2019) (4)
- Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study (2019) (4)
- First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590 (2022) (3)
- A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin (2016) (3)
- Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS). (2016) (3)
- Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months (2018) (3)
- A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study. (2013) (3)
- Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer. (2010) (3)
- Tumor response and symptom palliation from RAINBOW, a phase 3 trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer. (2020) (3)
- Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data (2019) (3)
- Comprehensive registry of esophageal cancer in Japan, 2015 (2022) (3)
- Avelumab (anti-PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial. (2018) (3)
- Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up. (2021) (3)
- Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer. (2019) (3)
- Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study (2017) (3)
- REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. (2020) (3)
- A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer. (2019) (3)
- Definitive chemoradiotherapy followed by salvage therapy for locoregional failure might be standard a treatment option for stages I-III esophageal squamous cell carcinoma (2005) (3)
- Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study). (2020) (3)
- 6099 POSTER The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumour Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC) (2011) (3)
- [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. (2012) (3)
- Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial (2018) (3)
- Impact of PD-L1 combined positive score (CPS) on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. (2021) (3)
- Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study. (2020) (3)
- Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study (2022) (3)
- A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial). (2018) (3)
- Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer. (2002) (3)
- Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2. (2019) (3)
- Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial (2019) (3)
- Clinical Impact of Oral Intake in Second-line or Third-line Chemotherapy for 589 Patients With Advanced Gastric Cancer (2021) (3)
- Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G. (2018) (3)
- Combination of Oxaliplatin and 5-Fluorouracil/Leucovorin for Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Standard Therapies (2019) (3)
- Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS. (2010) (3)
- Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802) (2015) (3)
- Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. (2014) (3)
- [Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey]. (2011) (3)
- P-268Impact of optimal morphologic response on survival in patients with KRAS wild-type unresectable colorectal liver metastases receiving an anti-EGFR or anti-VEGF agent (2015) (3)
- A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study. (2018) (3)
- Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors. (2019) (2)
- Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G) (2020) (2)
- No benefit from ramucirumab in first-line chemotherapy? (2017) (2)
- [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)]. (2011) (2)
- A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G. (2016) (2)
- ISY4-6Clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475) in KEYNOTE-012 (2015) (2)
- 532PAnalysis of efficacy and prognostic factors in second-line chemotherapy for BRAF V600E mutant metastatic colorectal cancer (2017) (2)
- A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer (2017) (2)
- LBA O-10 First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results (2022) (2)
- The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN). (2019) (2)
- SO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (2021) (2)
- Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101). (2022) (2)
- Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M) (2022) (2)
- Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months. (2017) (2)
- 209PCLINICAL VALIDATION OF A NOVEL MULTIPLEX KIT FOR ALL RAS MUTATIONS IN COLORECTAL CANCER: RESULTS OF RASKET(RAS KEY TESTING) PROSPECTIVE MULTICENTER STUDY. (2014) (2)
- [Incidence of infusion reactions induced by cetuximab chemotherapy]. (2011) (2)
- Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases (2018) (2)
- Prognostic and predictive significance of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), and HER2 in metastatic colorectal cancer (2005) (2)
- ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study. (2012) (2)
- A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study. (2017) (2)
- Peritoneum metastasis (PM) as a prognostic factor in metastatic gastric cancer (MGC) treated with anti-PD-1/PD-L1 monotherapy. (2017) (2)
- Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study (2021) (2)
- Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: A multicenter retrospective study. (2018) (2)
- 6121 POSTER Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC) (2011) (2)
- Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report. (2011) (2)
- Definitive chemoradiotherapy may be standard treatment options in clinical stage I esophageal cancer (2004) (2)
- FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. (2011) (2)
- Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (2014) (2)
- Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study (2021) (2)
- WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases. (2020) (2)
- Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC). (2014) (2)
- 6005 ORAL A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC) (2011) (2)
- A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results (QUATTRO study). (2017) (2)
- Differences in attitude toward adjuvant chemotherapy between colorectal cancer survivors and the medical staff of Japanese hospitals (2015) (2)
- 165PNeutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102 (2015) (2)
- The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer. (2015) (2)
- Randomized phase II study of S-1/CDDP plus TSU-68 versus S-1/CDDP in patients with advanced gastric cancer. (2013) (2)
- Abstract B54: Phase I study of ombrabulin in combination with cisplatin (CDDP) administered every 3 weeks to Japanese patients with advanced solid tumors. (2011) (2)
- The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN). (2019) (2)
- P1-5-18Re-introduction of taxane for patients with esophageal squamous cell carcinoma refractory to 5-FU, CDDP, and a taxane (2015) (2)
- 2150 Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (2)
- Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer (2021) (2)
- A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study. (2018) (2)
- A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma (2022) (2)
- Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. (2020) (2)
- The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma (2023) (2)
- EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs). (2019) (2)
- Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer. (2018) (1)
- Analysis of early tumor shrinkage (ETS) and depth of response (DpR) in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev): Results from a randomized phase II WJOG6210G trial. (2020) (1)
- Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial. (2018) (1)
- SPS-6WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP (2017) (1)
- Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study. (2021) (1)
- [Current Progress and Feasibility of Using Molecular-Targeted Agent Combinations for Metastatic Colorectal Cancer]. (2016) (1)
- P-163 Systemic chemotherapy for previously treated metastatic small bowel adenocarcinoma (2020) (1)
- A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer. (2017) (1)
- Global phase III trial of comparing mXELIRI+BV vs FOLFIRI+Bmab for 2nd line mCRC (AXEPT) Japanese population analysis. (2018) (1)
- O-0016RAINBOW: GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF RAMUCIRUMAB PLUS PACLITAXEL VS PLACEBO PLUS PACLITAXEL PATIENTS WITH PREVIOUSLY TREATED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA – PATIENT-REPORTED OUTCOMES AND PERFORMANCE STATUS (2014) (1)
- Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors. (2016) (1)
- PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy. (2021) (1)
- A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT). (2017) (1)
- 2301 Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538) in Patients with Esophageal Cancer: Preliminary Report (2015) (1)
- A patient with esophageal squamous cell carcinoma who had a complete pathological response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (2011) (1)
- O1-17-4CONTINUATION OF TRASTUZUMAB BEYOND PROGRESSION FOR HER2-POSITIVE ADVANCED GASTRIC CANCER AS SECOND-LINE TREATMENT (2014) (1)
- Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer. (2018) (1)
- A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer (2018) (1)
- Cediranib in combination with mFOLFOX 6 in Japanese patients with metastatic colorectal cancer : results from the randomised phase II part of a phase I / II study (2012) (1)
- 1217P Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study) (2022) (1)
- Pretreatment metabolomic markers associated with therapeutic responses to FOLFOX with bevacizumab in chemotherapy-naive patients with colorectal cancer. (2019) (1)
- Randomized phase II study comparing dose-escalated weekly paclitaxel versus standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer. (2013) (1)
- A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study (2022) (1)
- O1-3-1Comparison between NAC-S and CRT in overall survival for patients with esophageal squamous cell carcinoma (JCOG1406-A) (2015) (1)
- Phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pretreated patients with metastatic colorectal cancer. (2014) (1)
- Prognostic Factors for Patients With Metastatic Colorectal Cancer Receiving Protracted Venous Infusion of 5-FU (2002) (1)
- Pan-Asian adapted ESMO guidelines for the management of patients with metastatic oesophageal and gastric cancer. (2018) (1)
- Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: A multicenter retrospective study. (2017) (1)
- Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial (2020) (1)
- 169PSerum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer (2015) (1)
- The ATOM trial: A multicenter, randomized phase II study of modified FOLFOX6 plus bevacizumab and modified FOLFOX6 plus cetuximab for colorectal cancer with liver-limited metastases. (2016) (1)
- The final results of a multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201) (2016) (1)
- Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial) (2019) (1)
- Phase II study of oxaliplatin combined with S-1 (SOX) as first-line therapy for patients with advanced gastric cancer (AGC). (2009) (1)
- 1418P Chronological improvement in the survival of advanced gastric cancer patients in the past 15 years (2021) (1)
- Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake (2020) (1)
- Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: Literature-based analysis of 36 randomized trials. (2011) (1)
- PD-012Validation study of the 12-gene Recurrence Score (RS) in patients (pts) with stage II and III colon cancer (CC) without adjuvant chemotherapy; SUNRISE Study (2015) (1)
- Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intake (2020) (1)
- Clinical implication of using up both fluoropyrimidine (FU) and paclitaxel (PTX) in patients with severe peritoneal metastases (SPM) of gastric cancer (GC). (2021) (1)
- LBA3_PRRandomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT) (2017) (1)
- LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study). (2023) (1)
- KEYNOTE-061: pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer. (2018) (1)
- Adjuvant Chemotherapy for Gastric Cancer-Current Status and Future Perspective (2012) (1)
- P47.02 EV-202: Phase 2 Study of Enfortumab Vedotin for Previously Treated Advanced Solid Tumors Including Non-Small Cell Lung Cancer (2021) (1)
- Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study. (2018) (1)
- O1-3-2Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: a long-term comparison (2016) (1)
- O2-10-4Avelumab (MSB0010718C; anti-PD-L1), in Japanese patients with advanced gastric cancer: results from phase Ib trial (2016) (1)
- European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions (2022) (1)
- The location of colorectal cancer (right- vs. left-sided colon and rectum) affects the prevalence of BRAF V600E, non-V600E and PIK3CA mutations: a prospective registration study in the Aichi Cancer Network (2016) (1)
- Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer? (2020) (1)
- [Team medicine in chemotherapy for metastatic colorectal cancer]. (2013) (1)
- 450P The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC): Updated analysis (2020) (1)
- Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study (2019) (1)
- [Investigating the incidence of injection-site reactions associated with administration of oxaliplatin into a peripheral vein and management local adverse reactions]. (2011) (1)
- Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061) (2019) (1)
- 1244P Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study) (2022) (1)
- A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer. (2016) (1)
- Comparison between neoadjuvant chemotherapy followed by surgery (NAC-S) and definitive chemoradiotherapy (CRT) in overall survival for patients with clinical stage II-III esophageal squamous cell carcinoma (ESCC) (JCOG1406-A). (2015) (1)
- Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. (2011) (1)
- KRAS genotypes and outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2011) (1)
- Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study (2023) (1)
- Retrospective observational study of salvage line ramucirumab monotherapy (RAM) for patients (pts) with unresectable advanced gastric cancer (AGC) which was refractory to fluoropyrimidine and taxanes. (2018) (1)
- 208PReal-world advanced gastric cancer treatment patterns in Western and Asian countries (2017) (1)
- Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study. (2011) (1)
- Clinical Results of Definitive Chemoradiation Therapy for Cervical Esophageal Cancer: Comparison of Failure Pattern and Toxicities Between Intensity Modulated Radiation Therapy and 3-Dimensional Chemoradiation Therapy Group (2016) (1)
- Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial. (2020) (1)
- Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status. (2017) (1)
- 2113 Initial safety survey report from early post-marketing phase vigilance (EPPV) on TAS-102 for metastatic colorectal cancer (mCRC) (2015) (1)
- Immune monitoring of blood in advanced gastroesophageal adenocarcinoma patients treated with an anti-MMP9 monoclonal antibody in combination with nivolumab. (2020) (1)
- O-010KRAS and BRAF gene subgroup analysis in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients with metastatic colorectal cancer (2015) (1)
- Erratum: Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer (2014) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data. (2015) (1)
- Impact of sarcopenia on survival outcomes in patients (pts) with metastatic gastric cancer (mGC). (2017) (1)
- Histological subtype of gastric cancer in Japan. (2010) (1)
- Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Köhne model (Km). (2012) (1)
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. (2023) (1)
- Randomized phase II study comparing dose-escalated weekly paclitaxel (wPTX) versus standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC). (2013) (1)
- Establishment and validation of prognostic nomograms including HER2 status in metastatic gastric cancer. (2016) (1)
- PTEN/p-AKT expression as predictive markers for cetuximab in colorectal cancer. (2010) (1)
- 579PPrimary efficacy results and clinical impact of UGT1A1 genotype on safety from a Phase II study of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: The QUATTRO study (2017) (1)
- P4-10 The impact of neutrophil/lymphocyte ratio (NLR) on overall survival for patients with metastatic colorectal cancer (2021) (1)
- Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI (2016) (1)
- Was the unexpected result a response to reintroduction of effective chemotherapy? (2009) (0)
- P68-5 Prospective trial of comprehensive genomic profiling for patients with chemotherapy-naïve cancer (FIRST-Dx trial) (2022) (0)
- An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake. (2018) (0)
- 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC) (2020) (0)
- Cetuximab observational study as first-line therapy in patients with metastatic colorectal cancer. (2016) (0)
- 584PPredictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G) (2017) (0)
- 205PReal-world productivity, healthcare resource utilization (HRU), and quality of life (QOL) in patients with advanced gastric cancer (GC) in Korea and Japan (2017) (0)
- Tumor response and growth rate of nivolumab treatment in advanced gastric cancer: Real-world data from a large observational/translational study, JACCRO GC-08 (deliver trial). (2020) (0)
- 634PRisk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis (2017) (0)
- Implications for the American Joint Committee on Cancer staging systems on esophageal squamous cell cancer patients receiving multimodality therapy. (2014) (0)
- Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): A post hoc analysis of the WJOG4407G phase III study. (2018) (0)
- 1224P Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08) (2022) (0)
- Efficacy and safety of nivolumab and irinotecan as third-line chemotherapy for advanced gastric cancer: A multi-institutional retrospective study. (2020) (0)
- Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. (2018) (0)
- Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer. (2023) (0)
- Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study (2021) (0)
- Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial. (2019) (0)
- An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study. (2021) (0)
- [Retrospective analysis of tegafur/uracil (UFT) plus oral leucovorin (LV) regimen in patients with advanced colorectal cancer]. (2006) (0)
- P-134 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohorts (2022) (0)
- O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08) (2021) (0)
- P-80 A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study (2022) (0)
- QUANTITATIVE PREDICTION OF DRUG-DRUG INTERACTIONS: MECHANISM-BASED INHIBITION OF DRUG METABOLISM (1998) (0)
- P42-5 Optimal primary prophylaxis for febrile neutropenia during docetaxel, cisplatin, and 5-FU therapy for esophageal cancer (2022) (0)
- 2152 Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G study (2015) (0)
- Abstract 1974: Clonal and subclonal mutational landscapes in circulating tumor DNA in metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study (2020) (0)
- Predictive value of tumor growth rate during previous treatment for tumor response to regorafenib (REGO) and trifluridine/tipiracil (TFTD) in metastatic colorectal cancer (mCRC). (2018) (0)
- A Multicenter Phase-II Study of 5-FU , Leucovorin and Oxaliplatin ( FOLFOX 6 ) in Patients with Pretreated Metastatic Colorectal Cancer (2010) (0)
- Prognostic and predictive value of CA19-9 in metastatic colorectal cancer. (2013) (0)
- A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC 0808). (2013) (0)
- Authors & Collaborators _ RAISE study (2015) (0)
- Biomarker Analysis in A Randomized Phase 2 Study of Panitumumab Versus Cetuximab in Colorectal Cancer (WJOG6510GTR) (2020) (0)
- [Lower G. I./Colon and Rectum Cancer Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2019 for the Treatment of Colorectal Cancer-Major Revised Points]. (2019) (0)
- Phase Ib study of andecaliximab (GS-5745, ADX) in combination with S-1+platinum chemotherapy in Japanese subjects with advanced gastric or GEJ adenocarcinoma. (2019) (0)
- O2-11-3IMPLICATIONS FOR THE AJCC STAGING SYSTEMS ON ESOPHAGEAL SQUAMOUS CELL CANCER PATIENTS RECEIVING MULTIMODALITY THERAPY (2014) (0)
- 3) Immune Checkpoint Inhibitors for Gastrointestinal Tract Cancers (2019) (0)
- 1) Molecular-targeted Drug Therapy for Gastric Cancer (2012) (0)
- Identification of cancer hallmarks associated with benefit in advanced gastroesophageal adenocarcinoma patients treated with checkpoint blockade. (2020) (0)
- Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT (2019) (0)
- The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC) (2019) (0)
- Colon cancer with extensive invasion of the abdominal wall treated with neoadjuvant chemotherapy and a free anterolateral thigh flap (2022) (0)
- P-95 Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study (2022) (0)
- ATOM trial: a randomized phase II study of mFOLFOX6+Bmab vs. mFOLFOX6+Cmab for not-optimary resectable KRAS wt mCRC. (2018) (0)
- UvA-DARE ( Digital Academic Repository ) APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis (1998) (0)
- “Para‐lesional” Saline Injection Method for Assessment of Small Gastric Cancers by Endoscopic Ultrasonography (1996) (0)
- Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. (2016) (0)
- Is serum HER2-ECD testing significant for resectable gastric cancer? (2015) (0)
- 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE) (2016) (0)
- 676PPD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer (2017) (0)
- Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer. (2021) (0)
- Angiogenesis-related factors associated with nivolumab efficacy in patients with advanced gastric cancer after refractory or intolerant to ramucirumab-based therapy. (2021) (0)
- Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802) (2015) (0)
- [Molecular targeted therapy in colorectal cancer and its resistance]. (2009) (0)
- MO20-2 Efficacy of immune checkpoint inhibitors for gastrointestinal cancers with SWI/SNF complex genetic alterations (2022) (0)
- original Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer (2006) (0)
- Multicenter retrospective study of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT). (2023) (0)
- 388P Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial (2022) (0)
- Commentary: Clinical Trials Represent the Best Cancer Care. Or Do They? (2011) (0)
- Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial) (2019) (0)
- Predictors of therapeutic efficacy of anamorelin in patients with gastric, pancreatic, and colorectal cancer. (2023) (0)
- Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma. (2023) (0)
- Exploratory study of intraperitoneal paclitaxel plus mFOLFOX6 for gastric cancer patients with peritoneal metastasis and inadequate oral intake. (2017) (0)
- Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report (2022) (0)
- Proton Pump Inhibitor Use and the Efficacy of Capecitabine and Fluorouracil in Metastatic Colorectal Cancer: A Post Hoc Analysis of the AXEPT Randomised Phase III Trial (2020) (0)
- O3-9-4Phase 1b study of first-line Ramucirumab + Platinum + Fluoropyrimidine in Japanese Patients with advanced gastric cancer (2017) (0)
- Host-related biomarkers including gut microbiome to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08). (2022) (0)
- Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer (2016) (0)
- [Chemotherapy for esophageal cancer]. (2011) (0)
- Phase II trial of adjuvant mFOLFOX6 after metastasectomy for pulmonary metastasis of colorectal cancer: WJOG5810G. (2020) (0)
- [Lower G. I./Colon and Rectum Cancer Frontiers of Perioperative Treatment for Colorectal Cancer]. (2021) (0)
- Anti-angiogenesis inhibitor combined with immunotherapy for metastatic gastric or gastroesophageal adenocarcinoma. (2018) (0)
- Abstract OT1-02-04: Enfortumab vedotin 202: Phase 2 study of enfortumab vedotin for previously treated advanced solid tumors, including breast cancer (2022) (0)
- O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial (2021) (0)
- Post-Marketing Survey of Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: Interim Report of 3,005 Patients (2012) (0)
- Clinical impact of oral intake on second-line treatment of advanced gastric cancer. (2020) (0)
- Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study. (2023) (0)
- O3-15-4Development of nomograms for predicting survival in advanced gastric cancer (2015) (0)
- P-61 Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy (2022) (0)
- INACTIVATION MECHANISM OF HUMAN DIHYDROPYRIMIDINE DEHY DROGENASE BY 5-(2'-BROMOVINYL)URACIL, A METABOLITE OF THE ANTIVIRAL, SORIVUDINE (1997) (0)
- 6529 POSTER Lymph Node Size Is a Strong Prognostic Factor for Patients With Esophageal Cancer Treated by Chemoradiotherapy (2011) (0)
- O12-1 Ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma: RAM-NEC study (WJOG13420G) (2022) (0)
- [The Intention of Planning a Special Feature on "Where We Are Now, What the Problems Are, and Where We Are Going with Our Country's Medical Practice Guidelines"]. (2023) (0)
- [Potentiality of Immune Checkpoint Inhibitors for Advanced Esophageal and Gastric Cancer]. (2016) (0)
- Salvage chemotherapy versus best supportive care in patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane. (2015) (0)
- [Lower G. I./Colon and Rectum Cancer Updated Japanese Guidelines in Colon and Rectum Cancer]. (2017) (0)
- Treatment for locally advanced esophageal carcinoma complicated by fistulas: Case report (1996) (0)
- A multicenter, open-label, uncontrolled study of ONO-7643/anamorelin in cachexia patients with gastrointestinal cancer. (2018) (0)
- Oral Session 1: Gastric cancer O1 002 CORRELATION BETWEEN THE EFFECTS OF FIRST-LINE CHEMOTHERAPY AND SURVIVAL TIME FROM SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER (2012) (0)
- [A questionnaire survey on QOL and toxicity in colorectal cancer survivors who received adjuvant chemotherapy]. (2015) (0)
- A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR) (2019) (0)
- Abstract2103: Long-Term Results of Definitive Chemoradiotherapy for Clinical Stage I Squamous Cell Carcinoma of the Esophagus (2006) (0)
- Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis (2021) (0)
- MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors (2022) (0)
- Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group (2020) (0)
- Negative impact of cachexia during chemotherapy on survival as first-line chemotherapy for metastatic colorectal cancer. (2020) (0)
- Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant (2023) (0)
- Phase I Study of Ombrabulin in Combination with Cisplatin (CDDP) Administered Every 3 Weeks to Japanese Patients with Advanced Solid Tumors (2012) (0)
- Clinical outcome of pembrolizumab in clinical studies for advanced gastric and gastroesophageal junction (G/GEJ) cancer. (2017) (0)
- O1-17-2PROGNOSTIC IMPACT OF HER2 IMMUNOREACTIVITY IN HER2-POSITIVE GASTRIC CANCER TREATED WITH TRASTUZUMAB-BASED CHEMOTHERAPY (2014) (0)
- Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (2016) (0)
- Discrepancy between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: A post-hoc analysis (WJOG4407GSS2). (2018) (0)
- Observational study of first-line therapy, including cetuximab in cases of nonresectable colorectal cancer: CORAL (interim report). (2015) (0)
- Recursive partitioning for new classification of patients with esophageal cancer treated by chemoradiotherapy. (2012) (0)
- WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study). (2022) (0)
- P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer (2021) (0)
- Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study (2019) (0)
- MO35-4 Impact of omitting fluorouracil from FOLFIRI plus bevacizumab in second-line treatment of metastatic colorectal cancer (2021) (0)
- ' s response to reviews Title : A phase-II trial of combined chemotherapy with S-1 , oral leucovorin , and bevacizumab in heavily pretreated patients with metastatic colorectal cancer (2015) (0)
- P1-5-61Characterization of serum HER2 extracellular domain (ECD) level in patients with metastatic colorectal cancer (2015) (0)
- Abstract CT096: Phase 1b study of ramucirumab (RAM) in combination with fluoropyrimidine and platinum-based agents in Japanese patients (pts) with metastatic gastric/gastroesophageal junction adenocarcinoma (mGC) (2017) (0)
- MO27-5 Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma: a retrospective study (2022) (0)
- SO-19 A multicenter phase Ⅱ trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial (2021) (0)
- [Management for adverse events associated with FOLFIRI plus cetuximab or panitumumab]. (2015) (0)
- Thanking All Peer Reviewers. (2019) (0)
- Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients (pts) with untreated advanced gastric cancer (AGC). (2011) (0)
- O1-8-3TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib (2016) (0)
- 6513 POSTER Reporting Patient Characteristics and Stratification Factors in Randomized Trials of Systemic Chemotherapy for Advanced Gastric Cancer (2011) (0)
- A prospective survey of comprehensive score for financial toxicity (COST) in Japanese cancer patients. (2018) (0)
- Surgery for lymph node metastasis after complete response to chemotherapy and/or radiation therapy in patients with advanced esophageal cancer (2010) (0)
- Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab (2020) (0)
- 2343 Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD and RAINBOW) (2015) (0)
- REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progressive disease of nivolumab (NIV) therapy for metastatic gastric cancer (mGC). (2019) (0)
- Association of bevacizumab-free interval with efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer. (2014) (0)
- A case of duodenal carcinoid tumor completely resected by endoscopic mucosal resection (1998) (0)
- O1-6 REVIVE study: An observational study in chemotherapy (CTx) after nivolumab (NIVO) for advanced gastric cancer (AGC) (2022) (0)
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 (2018) (0)
- Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 (2021) (0)
- 6100 POSTER Prolonged Survival of Patients With Metastatic Colorectal Cancer Who Underwent First-line Oxaliplatin Based Chemotherapy With the Introduction of Molecular Targeting Agents and Curative Surgery (2011) (0)
- Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment. (2020) (0)
- The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study (2022) (0)
- Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study. (2021) (0)
- Abstract 5957: Molecular characteristics of gut microbiota in patients with gastric cancer: The DELIVER trial (JACCRO GC-08) (2022) (0)
- P-356 phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study (2020) (0)
- The efficacy and safety of FOLFIRI+BEV/mXELIRI+BEV by UGT1A1 polymorphisms in metastatic colorectal cancer AXEPT trial (2019) (0)
- The impacts of initiating regorafenib with reduced dose on treatment outcomes in metastatic colorectal cancer. (2023) (0)
- 359O_PR Efficacy and safety of pembrolizumab (MK-3475) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Subset analyses for Asia-pacific patients in KEYNOTE-012 (KN-012) B2 cohort (2016) (0)
- Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study (2021) (0)
- [Reinitiation of database registration of patients of esophageal neoplasm in Japan]. (2008) (0)
- Phase II study of S-1 plus irinotecan (SIR) in patients with advanced colorectal cancer. (2006) (0)
- [Ⅲ. A New Era of Chemotherapy for Advanced Gastric Cancer]. (2022) (0)
- JS3-3Molecular targeting agents combined with radiation therapy for esophageal cancer (2015) (0)
- [Chemotherapy for gastric cancer]. (2014) (0)
- 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST) (2022) (0)
- Association of folate intake and outcome of patients with advanced gastric cancer treated with first-line fluorouracil-based chemotherapy. (2010) (0)
- Impact of first-line bevacizumab (BV) on the clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with second-line FOLFIRI plus BV. (2014) (0)
- 6514 POSTER Genetic Polymorphism of IGF1 Predicts Recurrence in Patients With Gastric Cancer Who Have Undergone Curative Gastrectomy (2011) (0)
- Efficacy of Trastuzumab Containing Retreatment after Progression on Lapatinib Therapy in Japanese Patients with HER2-Positive Metastatic Breast Cancer (2012) (0)
- Immune Checkpoint Inhibitors Against Colon Cancer (2018) (0)
- Real-World Productivity, Healthcare Resource Utilization (Hru), and Quality of Life (Qol) in Patients With First-Line Advanced Gastric Cancer (Agc) in Korea and Japan (2018) (0)
- Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma (2022) (0)
- Recursive Partitioning for New Classification of Patients with Esophageal Cancer Treated by Chemoradiotherapy (2012) (0)
- [Transition of chemotherapy for metastatic colorectal cancer and recent advances]. (2010) (0)
- [Chemoradiotherapy for esophageal cancer]. (2009) (0)
- O1-9-5Metastatic colorectal cancer patients who achieved long progression-free survival by regorafenib or TAS-102 therapy (2016) (0)
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2022) (0)
- Final report of post-marketing survey of panitumumab in Japanese patients with unresectable advanced or recurrent colorectal cancer. (2013) (0)
- Definitive C hemoradiotherap y f or T 4 a nd/or M 1 L ymph N ode Squamous C ell C arcinoma o f t he E sophagus (1999) (0)
- Risk of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients with solid tumors who received systemic chemotherapy: two retrospective studies (2020) (0)
- MO5-4 Angiogenesis-related factors associated with nivolumab efficacy after ramucirumab therapy in advanced gastric cancer (2021) (0)
- Abstract CT164: Circulating tumor DNA analysis for predictive and prognostic factors in patients with metastatic colorectal cancer: An exploratory analysis from the phase III PARADIGM study (2018) (0)
- Neutrophil-to-lymphocyte ratio as a prognostic factor and its relationship to patient (pt) outcomes in the RAINBOW trial. (2020) (0)
- P1-5-16Exploratory analysis of prognostic subset in esophageal cancer patients previously treated with FU, Pt, taxane therapy (2015) (0)
- A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study (2021) (0)
- Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center (2023) (0)
- Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (2020) (0)
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (2022) (0)
- Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant (2012) (0)
- [I. Immunotherapy for Gastroenterological Cancer]. (2017) (0)
- [Which chemotherapy regimens should we choose for 1st or 2nd line of metastatic colorectal cancer?]. (2011) (0)
- 2356 Phase I dose-escalation study of nintedanib in Japanese patients with advanced hepatocellular carcinoma (HCC) and mild or moderate liver impairment (2015) (0)
- A translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial) (2018) (0)
- Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study (2023) (0)
- Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. (2023) (0)
- [Lower G. I./Colon and Rectum Cancer Recent Topics in Metastatic Colorectal Cancer]. (2022) (0)
- A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer (2015) (0)
- ISS1-1-1PF-05212384 + irinotecan Phase II study in metastatic colorectal cancer (mCRC): B2151005 Japanese lead-in-cohort (J-LIC) (2015) (0)
- MO36-4 Asian subgroup analysis in global POLAR program of calmangafodipir on top of mFOLFOX6 for the prevention of CIPN (2022) (0)
- Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G (2021) (0)
- Abstract 2140: Association between gene expression signatures and outcomes of pembrolizumab (pembro) and paclitaxel (pac) in advanced gastric cancer (GC): Exploratory analysis from KEYNOTE-061 (2022) (0)
- IS3. Gastric Cancer (2012) (0)
- Pembrolizumab vs chemotherapy as 2L therapy for advanced esophageal cancer: Japanese Subgroup Analysis in KEYNOTE-181 (2019) (0)
- P-57 An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18) (2022) (0)
- P-28 Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study (2021) (0)
- P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers (2021) (0)
- Differential association of proton pump inhibitors with efficacy of capecitabine and 5-fluorouracil in metastatic colorectal cancer: A post-hoc analysis from AXEPT phase III trial. (2020) (0)
- Plasma VEGF-A (pVEGF-A) level in efficacy analysis of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). (2018) (0)
- Phase I/II trial of chemoradiotherapy concurrent with S-1 and cisplatin in patients with clinical stage II/III esophageal carcinoma: Results of the Japan Clinical Oncology Group study JCOG 0604. (2014) (0)
- Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features (2019) (0)
- Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress. (2018) (0)
- Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer (2020) (0)
- [Lower G. I./Colon and Rectum Cancer Lower G. I. Tumor - Treatment for Rare Fraction in Lower G. I. Tumor]. (2018) (0)
- Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis (2021) (0)
- [Lower G. I./Colon and Rectum Cancer Diagnosis and Treatment of Various Rare Gene Alterations in Colorectal Cancer]. (2020) (0)
- Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial (2022) (0)
- P-99 A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases: WJOG10517G (2022) (0)
- P-155 A phase I study of FLOT as first-line therapy for Japanese patients with advanced gastric cancer including patients with or without severe peritoneal metastasis (2021) (0)
- Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study (2016) (0)
- Effect of first-line molecular targeted agents on the efficacy of second-line bevacizumab-containing regimen for metastatic colorectal cancer. (2016) (0)
- P-232Characterization of serum HER2 ECD level in patients with metastatic colorectal cancer (2015) (0)
- Immunotherapy for gastroenterological cancer. (2017) (0)
- Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for metastatic colorectal cancer patients. (2021) (0)
- 6579 POSTER Phase II Study of ABI-007 Given as an Every Three Weeks Schedule for Japanese Patients With Unresectable or Recurrent Gastric Cancer Refractory to 5-fluorouracil (5-FU) Containing Regimen (2011) (0)
- MO19-5 The association between prices and clinical benefit of approved drugs for solid tumors in Japan (2021) (0)
- 6096 Frequency of KRAS/BRAF mutations as predictive markers for Cetuximab in Japanese colorectal cancer patients (2009) (0)
- Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. (2018) (0)
- ISY-17-2UGT1A1 genotype as an indicator of neutropenia for FOLFOXIRI with bevacizumab in patients with mCRC (QUATTRO study) (2016) (0)
- Gastric cancer (GC) cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) in combination with nivolumab. (2023) (0)
- Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients (2013) (0)
- Trial in progress: A phase II study of second-line FOLFIRI plus panitumumab after first-line FOLFOX plus panitumumab for RAS wild-type colorectal cancer with evaluation of circulating tumor DNA. (2018) (0)
- Risk factors of nivolumab-induced pneumonitis in patients with solid tumors. (2018) (0)
- A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR) (2022) (0)
- Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer (2020) (0)
- LBA-4 Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer (2020) (0)
- Fluoropyrimidine (F) alone versus F plus platinum (P) as first-line chemotherapy in patients (pts) with advanced gastric cancer (AGC) and severe peritoneal metastasis (SPM): A multicenter observational study. (2018) (0)
- UGT1A1*6 genotype in Asian population and hard endpoint for locally advanced rectal cancer (2021) (0)
- Trastuzumab for a patient with heavily pretreated gastric cancer plus massive ascites and ovarian metastasis. (2012) (0)
- Preliminary Safety Data from a Randomized Phase II Study Comparing Dose-Escalated weekly Paclitaxel versus Standard-dose weekly Paclitaxel for Patients with Previously Treated advanced Gastric Cancer (2012) (0)
- Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer (2022) (0)
- 1444P Real-world nivolumab safety data from 650 patients with unresectable advanced or recurrent gastric cancer that had progressed after cancer chemotherapy: Summary of post-marketing surveillance in Japan (2020) (0)
- 205PDevelopment of nomograms including HER2 status for predicting survival in metastatic gastric cancer (2015) (0)
- O1–076FEASIBILITY OF OXALIPLATIN CONTAINING REGIMENS FOR ADVANCED GASTRIC CANCER (AGC) WITH PERITONEAL METASTASES (2013) (0)
- P-284Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup (2015) (0)
- 235P Phase 1b study of nimotuzumab in combination with concurrent chemoradiotherapy in Japanese patients with locally advanced esophageal cancer (2016) (0)
- Validation study of a prognostic classification system in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. (2012) (0)
- 153P Ramucirumab safety in East Asian (EA) compared to non-EA patients: A meta-analysis of adverse events (AEs) in 6 global, randomized, double-blind, phase 3 clinical trials (2016) (0)
- [A case of hepatic metastases from uveal melanoma treated effectively by transcatheter arterial chemoembolization with cisplatin and degradable starch microspheres]. (2012) (0)
- P-158 Clinical impact of oral intake in third-line treatment for advanced gastric cancer (2020) (0)
- First experience of a fully decentralized clinical trial: The dawn of a new era in oncology. (2023) (0)
- Observational study of the first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial. (2014) (0)
- Updated Immunotherapy for Gastric Cancer (2023) (0)
- 389P Risk factors of nivolumab-induced pneumonitis in patients with solid tumors (2018) (0)
- MO22-6 Second-line systemic therapy in patients with recurrent or metastatic adenoid cystic carcinoma (2021) (0)
- [Discrepancy in Gastric Cancer Chemotherapy between the Asia and West]. (2023) (0)
- Survival outcome of metastatic adenocarcinoma of esophagogastric junction in the trastuzumab era. (2016) (0)
- Correction to: Comprehensive Registry of Esophageal Cancer in Japan, 2011 (2018) (0)
- O3–048CANCER OF UNKNOWN PRIMARY SITE: REVIEW OF CONSECUTIVE CASES IN AICHI CANCER CENTER HOSPITAL (2013) (0)
- A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. (1996) (0)
- How to detect superficial type of colorectal neoplasms? - From a retrospective and a prospective analyses of endoscopic findings (1995) (0)
- Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer (2021) (0)
- Granite-1; Phase III Trial of Everolimus (EVE) in Previously Treated Patients with Advanced Gastric Cancer (AGC): Results of Japanese Population (2012) (0)
- Endoscopic Study of Differential Diagnosis between Benign Ulcers and Malignancies with Open Ulcers of the Stomach (1996) (0)
- SY5-5A JAPANESE POST-MARKETING SURVEILLANCE OF REGORAFENIB IN COLORECTAL CANCER PATIENTS: INTERIM REPORT (2014) (0)
- Real-world first-line advanced gastric cancer in western and Asian countries: Treatment patterns and impact on quality of life (QOL). (2018) (0)
- Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial. (2018) (0)
- A randomized phase II study to assess trastuzumab beyond progression in HER2-positive advanced gastric cancer: WJOG7112G. (2018) (0)
- Survival of patients with HER2-positive gastric cancer with introduction of trastuzumab. (2012) (0)
- 2. Systemic Pharmacotherapy for Gastrointestinal Cancers (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kei Muro?
Kei Muro is affiliated with the following schools:
